Gamze Guney Eskiler Selected Research

talazoparib

1/2022	Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
1/2022	The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer.
3/2021	Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells.
1/2020	Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
5/2019	BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
9/2018	Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gamze Guney Eskiler Research Topics

Disease

17	Neoplasms (Cancer) 07/2022 - 10/2018
13	Breast Neoplasms (Breast Cancer) 07/2022 - 12/2016
12	Triple Negative Breast Neoplasms 01/2022 - 05/2018
8	Prostatic Neoplasms (Prostate Cancer) 02/2022 - 10/2018
2	Hepatocellular Carcinoma (Hepatoma) 03/2022 - 07/2019
1	Infections 03/2022
1	Carcinoma (Carcinomatosis) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022
1	Neoplasm Metastasis (Metastasis) 10/2021

Drug/Important Bio-Agent (IBA)

7	Therapeutic UsesIBA 03/2022 - 09/2020
6	talazoparibIBA 01/2022 - 09/2018
5	Proteins (Proteins, Gene)FDA Link 07/2022 - 01/2020
4	AcidsIBA 03/2022 - 09/2020
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 03/2022 - 09/2020
3	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2022 - 04/2020
3	Hormones (Hormone)IBA 09/2021 - 10/2018
3	Tamoxifen FDA LinkGeneric 08/2019 - 12/2016
3	usnic acidIBA 08/2019 - 10/2018
2	Gemcitabine FDA Link 02/2022 - 01/2022
2	Acridine OrangeIBA 02/2022 - 01/2022
2	cabazitaxel FDA Link 02/2022 - 07/2021
2	abemaciclibIBA 01/2022 - 09/2021
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 05/2019
2	CurcuminIBA 01/2022 - 01/2020
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 09/2021
2	nobiletinIBA 04/2020 - 01/2019
2	Sorafenib (BAY 43-9006)FDA Link 07/2019 - 01/2019
2	Lipid NanoparticlesIBA 09/2018 - 07/2018
1	Matrix Metalloproteinases (MMPs)IBA 07/2022
1	Tissue Inhibitor of Metalloproteinase-2IBA 07/2022
1	Tissue Inhibitor of Metalloproteinase-1IBA 07/2022
1	ChitosanIBA 02/2022
1	Fluorouracil (Carac)FDA LinkGeneric 02/2022
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022
1	Dopamine (Intropin)FDA LinkGeneric 01/2022
1	Metal-Organic FrameworksIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	OligodeoxyribonucleotidesIBA 01/2022
1	CPG-oligonucleotideIBA 01/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022
1	Poly I-CIBA 01/2022
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	Annexin A5IBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 10/2021
1	1-methyltryptophanIBA 10/2021
1	CytokinesIBA 10/2021
1	vulpinic acidIBA 08/2021
1	sulfosalicylic acidIBA 08/2021
1	Toll-Like Receptor 4IBA 07/2021
1	taxaneIBA 07/2021
1	Valproic Acid (Depakote)FDA LinkGeneric 02/2021
1	Histones (Histone)IBA 02/2021
1	CateninsIBA 02/2021
1	Histone Deacetylase InhibitorsIBA 02/2021
1	protoporphyrin IXIBA 09/2020
1	FlavonoidsIBA 04/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	multidrug resistance-associated protein 1IBA 01/2020
1	enzalutamideIBA 08/2019
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019

Therapy/Procedure

5	Therapeutics 02/2022 - 05/2018
4	Photochemotherapy (Photodynamic Therapy) 03/2022 - 09/2020
3	Castration 02/2022 - 07/2021
2	Drug Therapy (Chemotherapy) 07/2022 - 07/2019
1	Aftercare (After-Treatment) 07/2022
1	Neoadjuvant Therapy 07/2022
1	Immunotherapy 10/2021
1	Semiconductor Lasers 09/2020
1	Lasers (Laser) 09/2020